Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing
Reexamination Certificate
2005-11-15
2005-11-15
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
C435S005000, C530S350000
Reexamination Certificate
active
06964763
ABSTRACT:
The present invention relates to a method for suppressing infectivity of HIV which includes contacting the HIV or a cell targeted by HIV with an effective amount of a thrombospondin or a thrombospondin analog. Other aspects of the invention relate to contraceptives, pharmaceutical compositions, and non-contraceptive prophylactic devices that include a carrier and a thrombospondin or a thrombospondin analog. Methods of inhibiting HIV infection in a patient, blocking HIV binding to a cell, blocking chemokine binding to its receptor, and treating or preventing inflammatory states in a patient are also disclosed.
REFERENCES:
patent: 5426100 (1995-06-01), Deutch et al.
patent: 5695930 (1997-12-01), Weinstein et al.
patent: 5840692 (1998-11-01), Deutch et al.
patent: 0 807 686 A2 (1997-11-01), None
patent: WO 92/17499 (1992-10-01), None
patent: WO 96/38480 (1996-12-01), None
Wu, Q. Y., et al., 1991, “Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin”, Proc. Natl. Acad. Sci. USA 88(15):6775-79.
Peterson, C. B:, et al., 1992, “Long range effects of amino acid substitutions in the catalytic chain of aspartate transcarbamoylase”, J. Biol. Chem. 267(4):2443-50.
Freed, E. O., et al., 1994, “Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production”, J. Virol. 68(8):5311-5320.
Valle, R. P., et al., 1998, “Mutagenesis of the NS3 protease of dengue virus type 2”, J. Virol. 72(1):624-32.
Yao, J., et al., 2000, “A single amino-acid substitution of a tyrosine residue in the Rubella virus E1 cytoplasmic domain blocks virus release”, J. Virol. 74(7):3029-36.
Handschuh, G., et al., 2001, “Single amino acid substitutions in conserved extracellular domains of E-cadherin differ in their functional consequences”, J. Mol. Biol. 314(3):445-54.
Back, D. J., 1999, “Pharmacological issues relating to viral resistance”, Infect. 27(Suppl. 2):S42-4.
Yarchoan, R., and S. Broder S. 1992, “Correlations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development”, J. Enzyme Inhibit. 6(1):99-111 (abstract provided).
Öberg, B. and L. Vrang, 1990, “Screening for new agents”, Eur. J. Clin. Microbiol. Infect. Dis. 9(7):466-471.
Gait, M. J., et al., 1995, “Progress in anti-HIV structure-based drug design”, Trends Biotech. 13(10):430-8.
Crombie, R., et al., 2001, “Peptides derived from salivary thrombospondin-1 replicate its anti-HIV effect: potential role in microbicide development”, J. Acquir. Immune Defic. Syndr. 27:91-97.
Schols, D., et al., 1997, “D RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE)”, J. Virol. 71(10):7300-4 (abstract provided).
Pichova, I., et al., 1997, “Peptide inhibitors of HIV-1 and HIV-2 proteases: a comparative study”, Leukemia 11(S3):120-2 (abstract provided).
Bellarosa D., et al., 1996, “New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors at the reverse transcriptase”, Antiviral Res. 30(2-3):109-24 (abstract provided).
Althaus, I. W., et al., 1993, “Kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-88204E”, Biochem. 32(26):6548-54 (abstract provided).
Crombie et al., “Blockdale of Human Immunodeficiency Virus Infectivity by Salivary Thrombospondin,”Journal of Investigative Medicine Annual Meeting of the Association of American Physicians45(3):201A (1997) (abstract).
Crombie et al., “Identification of a CD36-Related Thrombospondin 1-Binding Domain in HIV-1 Envelope Glycoprotein gp120: Relationship to HIV-1-Specific Inhibitory Factors in Human Saliva,”J Exp Med187(1):25-35 (1998).
Crombie et al., Lysosomal Integral Membrane Protein II Binds Thrombospondin-1,Journal of Biological Chemistry273(9): 4855-4863 (1998).
Lahav, J., “The Functions of Thrombspondin and its Involvement in Physiology and Pathophysiology,”Biochem Biophys Acta1182(1):1-14 (1993).
Tikhonenko et al., “Viral Myc Oncoproteins in Infected Fibroblasts Down-Modulate Thrombospondin-1, a Possible Tumor Suppressor Gene,”The Journal of Biological Chemistry271(48):30741-30747 (1996).
Bornstein, P., “Thrombospondins: Structure and Regulation of Expression,”The FASEB Journal6:3290-3299 (1992).
Sinnis et al., “Remnant Lipoproteins Inhibit Malaria Sporozoite Invasion of Hepatocytes,”J Exp Med184:945-954 (1996).
Crombie, R., et al., 1997, “Blockade of human immunodeficiency virus infectivity by salivary thrombospondin”, J. Invest. Med. (45(3):201A.
Crombie, R., et al., 1998, “Identificaiton of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva”, J. Exp. Med. 187(1):25-35.
Crombie Andrea Rene
Laurence Jeffrey C.
Nachman Ralph L.
Cornell Research Foundation Inc.
Nixon & Peabody LLP
Parkin Jeffrey S.
LandOfFree
Methods and compositions for inhibiting HIV infectivity and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibiting HIV infectivity and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibiting HIV infectivity and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3480724